Biogen and Eli Lilly Release New Data for Experimental Alzheimer's Drugs

New data released from the clinical trials of experimental Alzheimer’s drugs from Biogen (NASDAQ:BIIB) and Eli Lilly (NYSE:LLY) leave investors slightly disappointed, but patients undecided, and even hopeful, about their potential efficacy.
According to an article published by Forbes:
Both companies have committed to large trials to prove the drugs work in slowing the progression of Alzheimer’s in its early stages. They are trying to convince everybody else that they made the right decision.
For doctors and patients, the best course is probably just to reserve judgement until larger studies are available. It’s only investors, who want to value these companies based on the odds of success of the drugs, and scientists and other drug companies, who are deciding how to develop other experimental medicines, who are really going to take any action based on these results. And for them, the new results probably change little.
Click here to read the full article on Forbes.